The CKD enigma with misleading statistics and myths about CKD, and conflicting ESRD and death rates in the literature: Results of a 2008 US population-based cross-sectional CKD outcomes analysis

Renal Failure

Volumn 35, Issue 3, 2013, Pages 338-343

  Onuigbo, Macaulay A C ^a,b  

^a DEPARTMENT OF UROLOGY   (United States)

^b Mayo Clinic Health System   (United States)

Author keywords

Acute kidney injury (AKI); Chronic kidney disease (CKD); CKD staging; End stage renal disease (ESRD); Non progressors; Progressors; Renoprevention; Syndrome of rapid onset end stage renal disease (SORO ESRD)

Indexed keywords

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; HUMAN; KIDNEY FAILURE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING TEST; UNITED STATES; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; INCIDENCE; KIDNEY FAILURE, CHRONIC; MORTALITY;

CROSS-SECTIONAL STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84875022796     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.764272     Document Type: Review

References (32)

1. Moyer VA. On behalf of the US Preventive Services Task Force. Screening for chronic kidney disease:USPreventive Services task force recommendation statement. Ann Intern Med. August 28, 2012. doi:10.7326/0003-4819-157-8- 201210160-00533 [Epub ahead of print]
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):S1-S266
3. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: Applications and implications. Am J Kidney Dis. 2009;53 (3 Suppl. 3):S4-S16
4. Onuigbo MA. The natural history of chronic kidney disease revisited-A 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: A call for circumspection. Adv Perit Dial. 2009;25:85-88
5. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663
6. Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73:1310-1315
7. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010. Available at: http://www.usrds.org/2010/ADR-booklet-2010- lowres.pdf, http://www.usrds.org/2009/pdf/V2-02-INC-PREV-09.PDF. Accessed December 20, 2010
8. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161-165
9. Onuigbo M, Onuigbo N. Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med. 2011;171(22):2066
10. TheConcordCoalition. Escalating Health Care Costs and the Federal Budget, April 2, 2009. Available at: http://www.concordcoalition. org/files/uploaded- for-nodes/docs/Iowa-Handout-final.pdf. Accessed September 12, 2011
11. The Henry J. Kaiser Family Foundation. Snapshots: Health Care Spending in the United States and Selected OECD Countries, April 2011. Available at: http://www.kff.org/insurance/snapshot/OECD042111.cfm. Accessed September 12, 2011
12. Centers for Medicare and Medicaid Services. National Health Expenditure Projections 2010-2020. Available at: http://www.cms. gov/ NationalHealthExpendData/downloads/proj2010.pdf. Accessed September 21, 2011
13. Sikaneta T, Abdolell M, Taskapan H, et al. Variability in CKD stage in outpatients followed in two large renal clinics. Int Urol Nephrol. 2011. doi:10.1007/s11255-011-9934-9
14. Onuigbo MA, Onuigbo NT. Variability in CKD stage in outpatients followed in two large renal clinics: Implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression. Int Urol Nephrol. 2012; 44(5);1589-1590 [Epub 2011 Aug 30]
15. Sikaneta T, Roscoe J, Fung J, et al. Variability in CKD stage in outpatients followed in two large renal clinics: Implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression: Response to Dr. Onuigbo. Int Urol Nephrol. 2012;44(5);1591-1592 [Epub 2011 Oct 14]
16. Onuigbo MA. The validity of current CKD staging paradigms revisited and disputed: A 2-year snap shot of stage IV CKD patients in a Mayo Clinic laboratory database: A call for process reengineering in nephrology practice. J Am Soc Nephrol. 2011;22:686A (SA-PO2472) (Abstract
17. Okusa MD, Chertow GM, Portilla D; Acute Kidney Injury Advisory Group of the American Society of Nephrology. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol. 2009;4(3):520-522 [Epub 2009 Feb 18]
18. Onuigbo MA. Syndrome of rapid-onset end-stage renal disease: A new unrecognized pattern of CKD progression to ESRD. Ren Fail. 2010;32(8):954-958
19. Onuigbo MAC, Onuigbo N. Syndrome of rapid onset endstage renal disease revisited-Observations from two chronic kidney disease populations in two continents. US Nephrology. 2010;5(2):81-85
20. Onuigbo MA, Onuigbo N. Chronic Kidney Disease and RAAS Blockade: A New View of Renoprotection. London: Lambert Academic Publishing GmbH 11 & Co. KG; 2011
21. Onuigbo MAC, Onuigbo NTC. The syndrome of rapid onset end-stage renal disease (SOROESRD)-A new Mayo Clinic dialysis services experience, January 2010-February 2011. In: Di Iorio B, Heidland A, Onuigbo M, Ronco C, eds. Hemodialysis: How, When and Why. New York: NOVA Publishers; 2012:443-485
22. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857-1863
23. O'Hare AM,Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18:2758-2765
24. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD. Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract. 2008;109: C109-c118
25. Yoshida T, Takei T, Shirota S, et al. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. Intern Med. 2008;47:1859-1864
26. Conway B, Webster A, Ramsay G, et al. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Nephrol Dial Transplant. 2009;24:1930-1937
27. Onuigbo MAC. Reno-prevention vs. reno-protection: A critical re-Appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET-A call for more circumspection. QJM. 2009;102:155-167 [Epub ahead of print January 5 2009]
28. Onuigbo M. Renoprevention: A new concept for re-engineering nephrology care: An economic impact and patient outcome analysis of two hypothetical patient management paradigms in the CCU. Ren Fail. 2013;35(1):23-28
29. OnuigboMAC. CKD express ©-A new IT-software proposed for a paradigm change in CKD care. Open Med Inform J. 2012;6:26-27
30. Bansal N, Hsu CY. Long-term outcomes of patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4:532-533
31. Tsalamandris C, Allen TJ, Gilbert RE, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43:649-655
32. Onuigbo MA. Causes of renal failure in patients with type 2 diabetes mellitus. J Am Med Assoc. 2003;290:1855